(Q38104492)

28 August 2017

title

Mechanistic / mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia (English)

1 reference

28 August 2017

1 reference

1

Atsushi Hirao

1 reference

28 August 2017

Takayuki Hoshii

2

1 reference

28 August 2017

publication date

9 June 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

104

1 reference

28 August 2017

issue

8

1 reference

28 August 2017

page(s)

977-982

1 reference

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

28 August 2017

cites work

1 reference

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

Molecular pathology of tumor-initiating cells: lessons from Philadelphia chromosome-positive leukemia

21 January 2018

1 reference

Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9.

21 January 2018

1 reference

Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells

21 January 2018

1 reference

21 January 2018

1 reference

Molecular mechanisms of mTOR-mediated translational control

21 January 2018

1 reference

mTOR signaling in growth control and disease

21 January 2018

1 reference

Metabolic regulation of hematopoietic stem cells in the hypoxic niche

21 January 2018

1 reference

Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling

21 January 2018

1 reference

Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb

21 January 2018

1 reference

PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis.

21 January 2018

1 reference

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

21 January 2018

1 reference

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

21 January 2018

1 reference

PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding

21 January 2018

1 reference

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

21 January 2018

1 reference

TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth

21 January 2018

1 reference

TSC2 mediates cellular energy response to control cell growth and survival

21 January 2018

1 reference

AMPK phosphorylation of raptor mediates a metabolic checkpoint

21 January 2018

1 reference

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

21 January 2018

1 reference

Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling

21 January 2018

1 reference

Regulation of TORC1 by Rag GTPases in nutrient response

21 January 2018

1 reference

The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1

21 January 2018

1 reference

Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids

21 January 2018

1 reference

An emerging role of mTOR in lipid biosynthesis.

21 January 2018

1 reference

SREBPs: transcriptional mediators of lipid homeostasis

21 January 2018

1 reference

mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway

21 January 2018

1 reference

Direct control of mitochondrial function by mTOR.

21 January 2018

1 reference

mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex

21 January 2018

1 reference

21 January 2018

Autophagy and metabolism

1 reference

Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy

21 January 2018

1 reference

The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.

21 January 2018

1 reference

Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling

21 January 2018

1 reference

Activation of mTORC2 by association with the ribosome

21 January 2018

1 reference

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1

21 January 2018

1 reference

SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity

21 January 2018

1 reference

Maintenance of genomic integrity in hematopoietic stem cells

21 January 2018

1 reference

Cytokine signals modulated via lipid rafts mimic niche signals and induce hibernation in hematopoietic stem cells

21 January 2018

1 reference

Foxo3a is essential for maintenance of the hematopoietic stem cell pool.

21 January 2018

1 reference

FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress

21 January 2018

1 reference

Foxo3 is essential for the regulation of ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of hematopoietic stem cells.

21 January 2018

1 reference

TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species

21 January 2018

1 reference

mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization

21 January 2018

1 reference

mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells

21 January 2018

1 reference

Maintenance of hematopoietic stem cells through regulation of Wnt and mTOR pathways

21 January 2018

1 reference

Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells

21 January 2018

1 reference

mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion.

21 January 2018

1 reference

Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression

21 January 2018

1 reference

Exploiting the mammalian target of rapamycin pathway in hematologic malignancies

21 January 2018

1 reference

Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies

21 January 2018

1 reference

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis

21 January 2018

1 reference

Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

21 January 2018

1 reference

A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

21 January 2018

1 reference

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

21 January 2018

1 reference

Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins

21 January 2018

1 reference

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

21 January 2018

1 reference

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

21 January 2018

1 reference

mTORC1 is essential for leukemia propagation but not stem cell self-renewal

21 January 2018

1 reference

PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention

21 January 2018

1 reference

The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23648144

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23648144

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23648144

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/CAS.12189

1 reference

28 August 2017

0 references

1 reference